Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Stelara data likely to encourage switch from first-line TNF inhibitors in psoriasis

This article was originally published in Scrip

Executive Summary

Sometimes long-term drug safety data doesn’t do much to differentiate a drug. But in the case of Stelara (ustekinumab), Janssen’s anti-p40 monoclonal antibody, new five-year data might shift it from mainly second- to mainly first-line therapy in severe psoriasis. If the safety data convinces doctors, the “new kid on the biologic block” may start to displace current dermatological first picks, TNF inhibitors such as Amgen’s Embrel.






Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts